HPV and Cervical Cancer Epidemiology - Current Status of HPV Vaccination in India

  • Published : 2016.08.01


Cervical cancer (CaCx) is the second most fatal cancer contributing to 14% of cancers in Indian females, which account for 25.4% and 26.5% of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing. There is no Indian national policy on CaCx prevention, and screening of asymptomatic females against CaCx is practically non-existent. HPV vaccines can make a major breakthrough in the control of CaCx in India which has high disease load and no organized screening program. Despite the Indian Government's effort to introduce HPV vaccination in the National Immunization Program and bring down vaccine cost, challenges to implementing vaccination in India are strong such as: inadequate epidemiological evidence for disease prioritization, duration of vaccine use, parental attitudes, and vaccine acceptance. This paper reviews the current epidemiology of CaCx and HPV in India, and the current status of HPV vaccination in the country. This article stresses the need for more research in the Indian context, to evaluate interventions for CaCx and assess their applicability, success, scalability and sustainability within the constraints of the Indian health care system.


  1. Adams M, Jasani B, Fiander A (2007). Human pailloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine, 25, 3007-13.
  2. Adams M, Jasani B, Fiander A (2009). Prophylactic HPV vaccination for women over 18 years of age. Vaccine, 27, 3391-4.
  3. Aggarwal R, Gupta S, Nijhawan R, et al (2009). Prevalence of high-risk human papillomavirus infections in women with benign cervical cytology: A hospital based study from North India. Indian J Cancer, 43, 110-16.
  4. Aggarwal R , Sachdeva RK, Naru J, et al (2012). HPV genotyping in north Indian women infected with HIV. Int J Gynecol Pathol, 31, 475-81.
  5. Arora R, Kumar A, Prusty BK, et al (2005). Prevalence of highrisk human papillomavirus (HR- HPV types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol, 121, 104-9.
  6. Aswathy S, Quereshi MA, Kurian B, Leelamoni K (2012). Cervical cancer screening: current knowledge and practice among women in a rural population of Kerala, India. Indian J Med Res, 136, 205-10.
  7. Bahmanyar ER, Paavonen J, Naud P, et al (2012). Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women females at enrolment in the multinational PATRICIA trial. Gynecol Oncol, 127, 440-50.
  8. Basu P, Roychowdhury S, Bafna UD, et al (2009). Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev, 10, 27-34.
  9. Basu P, Mittal S (2011). Acceptability of human papillomavirus vaccine among the urban, affluent and educated parents of young girls residing in Kolkata, Eastern India. J Obstet Gynaecol Res, 37, 393-401.
  10. Basu P, Mittal S, Bhaumik S, et al (2013). Prevalence of high-risk human papillomavirus and cervical intraepithelial neoplasias in a previously unscreened population--a pooled analysis from three studies. Int J Cancer, 132, 1693-9.
  11. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL (2008). A meta analysis of human pailloma virus type-distribution in women from South Asia: implications for vaccination. Vaccine, 26, 2811-7.
  12. Bhatla N, Dar L, Rajkumar PA, et al (2008). Human pailloma virus-type distribution in women with and without cervical neoplasia in north India. Int J Gynecol Pathol, 27, 426-30.
  13. Bosch FX, Manos MM, Munoz N, et al (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 87, 796-802.
  14. Brinton LA, Reeves WC, Brenes MM, et al (1989) The male factor in the etiology of cervical cancer among sexually monogamous women . Int J Cancer, 44, 199-203.
  15. Capalash N, Sobti RC (1999). Epidemiology of cervical cancer case control study on north Indian population. Indian J Cancer, 36, 179-85.
  16. Castellsague X, Bosch FX, Munoz N, et al (2002). Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med, 346, 1105-12.
  17. CDC (2013). Human Papillomavirus (HPV) -Associated Cancers. WWW page. URL: Last accessed February 24, 2016
  18. Celentano DD, Klassen AC, Weisman CS, Rosenshein NB (1987). The role of contraceptive use in cervical cancer: the Maryland Cervical Cancer Case-Control Study. Am J Epidemiol, 126, 592- 604.
  19. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008). Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol, 26, 612-9.
  20. Chen HC, Schiffman M, Lin CY, et al (2011). Persistence of type specific human papillomavirus infection and increased longterm risk of cervical cancer . J Natl Cancer Inst, 103, 1387-96
  21. Chhabra S, Bhavani M, Mahajan N, Bawaskar R (2010). Cervical cancer in Indian rural women females: trends over two decades. J Obstet Gynaecol, 30, 725-8.
  22. Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-8
  23. Cuschieri KS, Cubie HA, Whitley MW, et al (2004). Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol, 57, 68-72.
  24. Das D, Rai AK, Kataki AC, et al (2013). Nested multiplex PCR based detection of human papillomavirus in cervical carcinoma patients of North- East India. Asian Pac J Cancer Prev, 14, 785-90.
  25. Denny L, Sankaranarayanan R (2006). Secondary prevention of cervical cancer. Int J Gynaecol Obstet, 94, 65-S70.
  26. Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F (2011). Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an ageperiod- cohort analysis. Br J Cancer, 105, 723-30.
  27. Diaz M, Kim JJ, Albero G, et al (2008). Health and econ.omic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer, 99, 230-8.
  28. Dikshit R, Gupta PC, Ramasundarahettige C, et al (2012). Cancer mortality in India: a nationally representative survey. Lancet, 379, 1807-16.
  29. Dochez C, Bogers JJ, Verhelst R, Rees H (2014). HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine, 32, 1595-601.
  30. Datta S, Agarwal M, Chatterjee S, et al (2005).. Detection of human papillomavirus in women attending Pap cervical screening camp at a peripheral hospital of North-Eastern India. Med J Armed Forces India, 71, 182-5.
  31. Dutta S, Begum R, Mazumder ID, et al (2012). Prevalence of human papillomavirus in women without cervical cancer: a population-based study in Eastern India. Int J Gynecol Pathol, 31, 178-83.
  32. Dutta S, Biswas N, Mukheriee G (2013). Evaluation of sociodemographic factors for non compliance to treatment in locally advanced cases of cancer cervix in a rural medical college hospital in India. Indian J Palliat Care, 19, 158-65
  33. Emeka EO, Ifeanyichukwu DE, Chinwendu AF, Mohammmed AB, Henry N (2012). The influence of reproductive factors on genital human pailloma virus. Internet J Gynecol Obstet, 16.
  34. Evander M, Edlund K, Gustafsson A, et al (1995). Human papillomavirus infection is transient in young women females: a population based cohort study. J Infectious Diseases, 171, 1026-30.
  35. Farhath S, Vijaya PP, Mumtaj P (2013). Cervical cancer : is vaccination necessary in India? Asian Pac J Cancer Prev, 14, 2681-4.
  36. Final Report of the Committee appointed by the Govt. of India, (vide notification No. V.25011/160/2010-HR dated 15th April, 2010) to enquire into "Alleged irregularities in the conduct of studies using Human Pailloma virus (HPV) vaccine" by PATH in India. February, 2011. Available at report.pdf. Last accessed on 10.05.2015
  37. Franceschi S, Castellsague X, Dal Maso L, et al (2002). Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer, 86, 705-11.
  38. Franceschi S, Rajkumar T, Vaccarella S, et al (2003). Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer, 107, 127-33.
  39. Franceschi S, Rajkumar R, Snijders PJ, et al (2005). Papillomavirus infection in rural women in southern India. Br J Cancer, 92, 601-6.
  40. Franco EL, Duarte-Franco E, Ferenczy A (2003). Prospects for controlling cervical cancer at the turn of the century. Salud Publica Mex, 45, 367-75.
  41. Ghosh I, Ghosh P, Bharti AC, et al (2012). Prevalence of human papillomavirus and co-existent sexually transmitted infections among female sex workers, men having sex with men and injectable drug abusers from eastern India. Asian Pac J Cancer Prev, 13, 799-802.
  42. Gavi, Alliance partnership strategy with India, 2016-2021. WWW page. URL: alliance-partnership-strategy-with-india,-2016-2021. Last accessed February 24, 2016
  43. Globocan (2012a). Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. WWW page. URL: Last accessed February 24, 2016
  44. Globocan (2012b).Predictions: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. WWW page. URL: Last accessed February 24, 2016
  45. Globocan (2012c). World-both sexes estimated incidence by age. WWW page. URL: age_ specific_table_r.asp? Last accessed February 24, 2016
  46. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al (2005). Cost effectiveness of cervical screening in five developing countries. N Eng J Med, 353, 2158-68.
  47. Goodman MT, Shvetsov YB, McDuffie K, et al (2008). Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: hawaii human papillomavirus cohort study. Cancer Res, 68, 8813-24.
  48. Hariri S, Dunne E, Saraiya M, Unger E, Markowitz L (2011). Chapter 5: Human Papillomavirus (HPV). In VPD Surveillance Manual, 5th edn; ed Roush, S.W. and Baldy, L.M. Available at
  49. Harper DM, Demars LR (2014). Primary Strategies for HPV Infection and CaCx Prevention. Clin Obstetrics Gynecol, 57, 256-78.
  50. Health Impact News (2016). TV2 Denmark Documentary on HPV Vaccine Shows Lives of Young Women Ruined. WWW page. URL: tv2-denmark-documentary-on-hpv-vaccine-shows-lives-ofyoung- women-ruined.
  51. Hernandez BY, Wilkens LR, Zhu X, et al (2008). Transmission of human pailloma virus in heterosexual couples. Emerging Infectious Diseases, 14, 888-94.
  52. Herrero R, Castle PE, Schiffman M, et al (2005). Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis, 191, 1796-807
  53. Hildesheim A, Brinton LA, Mallin K, et al (1990). Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. Epidemiol, 4, 266-72
  54. Hussain MA, Pati S, Swain S, et al (2012). Pattern and trends of cancer in Odisha, India: a retrospective study. Asian Pac J Cancer Prev, 13, 6333-36
  55. IARC Working Group. (1995). Human pailloma viruses. IARC Monographs on the evaluation of carcinogenic risks to humans. WWW page. URL: ENG/Monographs/vol64/. Last accessed February 24, 2016
  56. I.A.R.C. (2007). Monographs on the evaluation of carcinogenic risks to humans. Volume 90: Human Papillomaviruses. WWW page. URL: Monographs/vol90/. Last accessed February 24, 2016
  57. Joshi S, Babu JM, Jayalakshmi D , et al (2014). Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India. Vaccine, 32, 1079-85
  58. Kawana K, Yasugi T, Taketani Y (2009). Human papillomavirus vaccines: Current issues and future. Indian J Med Res, 130, 341-7.
  59. Lehtinen M, Paavonem J (2004). Vaccination against human pailloma viruses shows great promise. Lancet, 364, 1731-2
  60. Liao SF, Lee WC, Chen HC, et al (2012). Baseline human papillomavirus infection, high vaginal parity, and their interaction on cervical cancer risks after a follow-up of more than 10 years. Cancer Causes Control, 23, 703-708.
  61. Mane A, Nirmalkar A, Risbud AR, et al (2012). HPV genotype distribution in cervical intraepithelial neoplasia among HIV-infected women in Pune, India. PLoS One, 7, 38731.
  62. Markowitz LE, Dunne EF, Saraiya M, et al (2014). Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). WWW page. URL: mmwrhtml/rr6305a1.htm. Last accessed February 24, 2016
  63. Mattheij I, Pollock AM, Brhlikova P. (2012). Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness. J R Soc Med, 105, 250-62
  64. Miller AB, Nazeer S, Fonn S, et al (2000). Report on consensus conference on cervical cancer screening and management. Int J Cancer, 86, 440-47.<440::AID-IJC22>3.0.CO;2-A
  65. Munoz N (2000). Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol, 19, 1-5.
  66. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer . New Engl J Med, 348, 518-27.
  67. Munoz N, Castellsague X, deGonzalez AB, Gissmann L (2006). HPV in the etiology of human cancer. Vaccine, 24, 1-10.
  68. Nanda K, McCrory DC, Myers ER, et al (2000). Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med, 132, 810-9.
  69. Nandakumar A, Ramnath T, Chaturvedi M (2009).The magnitude of cancer cervix in India. Indian J Med Res, 130, 219-21.
  70. National Cancer Control Programme (2002). Fifty years of cancer control in India. WWW page. URL: http://www. Last accessed February 24, 2016of India. Government of India, New Delhi.
  71. National Cancer Registry Program (2013). Leading sites of cancer. WWW page. URL: ALL_NCRP_REPORTS/PBCR_REPORT_2009_2011/ ALL_CONTENT/PDF_Printed_Version/Chapter2_Printed. pdf. Last accessed February 24, 2016
  72. National Cancer Registry Program (2013). Consolidated report of hospital based cancer registries: 2007-2011. WWW page. URL: HBCR_REPORT_2007_2011/ALL_CONTENT/Printed_ Version.htm. Last accessed February 24, 2016
  73. National Cancer Registry Program (2013). Three year report of population based cancer registries: 2009-2011. WWW page. URL: Version.htm. Last accessed February 24, 2016
  74. Parazzini F, Negri E, La Vecchia C, Fedele L (1989). Barrier methods of contraception and the risk of cervical neoplasia. Contracept, 40, 519-30.
  75. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002).Cancer incidence in five continents. IARC Scientific Publication, 8, 155.
  76. Peedicayil A, Thiyagarajan K, Gnanamony M, et al (2009). Prevalence and risk factors for human papillomavirus and cervical intraepithelial neoplasia among HIV-positive women females at a tertiary level hospital in India. J Low Genit Tract Dis, 13, 159-64.
  77. Pett M, Coleman N (2007). Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol, 212, 356-67.
  78. Pisani P, Parkin DM, Bray F, Ferlay J (1999). Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer, 83, 18-29
  79. Ramanathan M, Varghese J (2010). The HPV vaccine demonstration projects: we should wait, watch and learn. Indian J Med Ethics, 7, 43-5.
  80. Rastogi T, Devesa S, Mangtani P, et al (2008). Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol, 37, 147-60
  81. Rautava J, Syrjanen S (2011). Human pailloma virus infections in the oral mucosa. Journal of the American Dental Association, 142, 905-14
  82. Rositch AF, Koshiol J, Hudgens MG, et al (2013). Patterns of persistent genital human papillomavirus infection among women females worldwide: a literature review and metaanalysis. Int J Cancer, 133, 1271-85.
  83. Sankaranarayanan R, Chatterji R, Shastri SS, et al (2004). Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer, 112, 341-47
  84. Sankaranarayanan R, Nene BM, Dinshaw KA, et al (2005). A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer, 116, 617-23.
  85. Sankaranarayanan R, Esmy PO, Rajkumar R, et al (2007). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu: a cluster-randomised trial. Lancet, 370, 398-406.
  86. Sankaranarayanan R, Bhatla N, Gravitt PE, et al (2008). Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine, 26, 43-52.
  87. Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural India. N Engl J Med, 360, 1385-94.
  88. Sarkar K, Bhattacharya S, Bhattacharyya S, et al (2008). Oncogenic human pailloma virus and cervical pre-cancerous lesions in brothel-based sex workers in India. J Infect Public Health, 1, 121-8.
  89. Sarma U, Mahanta J, Borkakoty B, Sarmah B (2015). Distribution of human pailloma virus infections of uterine cervix among women of reproductive age-a cross sectional hospital-based study from North East India. Asian Pac J Cancer Prev, 16, 1519-23
  90. Satija A. Cervical cancer in India. South Asia centre for chronic disease. WWW page. URL: Last accessed February 24, 2016
  91. Schabath MB, Villa LL, Lazcano-Ponce E, et al (2012). Smoking and human papillomavirus (HPV) infection in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev, 21, 102-10.
  92. Singhal T (2008). Indian Academy of Pediatrics Committee on Immunisation (IAPCOI)-Consensus Recommendations on Immunization. Indian Pediatr, 45, 635-48
  93. Sowjanya AP, Jain M, Poli UR, et al (2005). Prevalence and distribution of high-risk human pailloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women females in Andhra Pradesh, India. BMC Infect Dis, 5, 116.
  94. Srivastava S, Gupta S, Roy JK (2012). High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic females of eastern Uttar Pradesh, India: a population-based study. J Biosci, 37, 63-72.
  95. Stjernsward J, Eddy D, Luthra UK, Stanley K (1987). Plotting a new course for cervical cancer in developing countries. World Hlth Frm, 8, 42-45.
  96. Sudenga SL, Shrestha S. (2013).Key considerations and current perspectives of epidemiological studies. Int J Infect Dis, 17, 216-20.
  97. Syrjanen K. (2011). Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. Eur J Gynaecol Oncol, 32, 17-33.
  98. Takiar R, Srivastav A. (2008). Time trend in breast and cervix cancer of women in India-(1990-2003). Asian Pac J Cancer Prev, 9, 777-80.
  99. Teixeira NCP, Araujo ACL, Correa CM, et al (2012). Prevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women . Braz J Infect Dis, 16, 164-9.
  100. The Asian Age. Government orders HPV vaccine study (2015). WWW page. URL: Last accessed February 24, 2016
  101. The FUTURE II Study Group (2007). Quadrivalent vaccine against Human Papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 356, 1915-27.
  102. Vinodhini K, Shanmughapriya S, Sanmugham S, et al (2012). Prevalence of high-risk HPV and associated risk factors in cases of cervical carcinoma in Tamil Nadu, India. Int J Gynaecol Obstet, 119, 253-6.
  103. Walboomers J, Jacobs M, Manos M, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  104. WHO (2005). Vaccine Introduction Guidelines: adding a vaccine to a national immunization programme -decision and implementation. WWW page. URL: . Last accessed February 24, 2016
  105. WHO (2009).WHO issues position on inclusion of human papilloma virus vaccines in routine immunization programmes. WWW page. URL: vaccination/en/. Last accessed February 24, 2016
  106. WHO (2009). Weekly Epidemiological Record. Geneva; World Health Organization; Human papillomavirus vaccines. WWW page. URL: Last accessed February 24, 2016
  107. WHO (2016). Information Centre on HPV and Cervical cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. WWW page. URL: Last accessed on 10.05.2015